Studies of golimumab yield positive results

06/12/2008 | Forbes

New findings are adding to evidence that golimumab, an injectable drug, holds promise as a treatment for rheumatoid arthritis when used in combination with methotrexate. One study found that 50-mg and 100-mg doses of golimumab caused disease remission in more than 30% of patients already on methotrexate, compared with 13% of those who received placebo and methotrexate. In another trial, 38% of patients who took golimumab and methotrexate experienced a 50% reduction in symptoms, while only 29% of those who got placebo plus methotrexate experienced similar improvement.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC